Stem cell-derived vesicles ameliorate liver fibrosis | IJN - Dove Medical Press

Summary

The article delves into the use of biotechnology to engineer mesenchymal stem cell-derived extracellular vesicles (MSC-sEVs) loaded with Bone morphogenetic protein 7 (BMP7) as a novel therapeutic strategy to target and revert activated hepatic stellate cells (aHSCs) for liver fibrosis treatment. It highlights the genetic engineering of MSCs for overexpressing BMP7, leading to the production of BMP7+sEVs, which demonstrate increased targeting to aHSCs and an enhanced capability in reversing the fibrotic process in the liver. The key concepts and tags connect through the role of MSC-sEVs in cell therapy for liver fibrosis, emphasizing advancements in stem cell biotechnology, cell biology, and potential stem-cell therapy applications.